A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).
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Introduction
Ganetespib is a next-generation resorcinol-based small molecule inhibitor of the heat-shock protein 90 (Hsp90), a chaperone protein critical to the stabilization and activation of numerous oncogenic proteins. By targeting Hsp90, ganetespib simultaneously inhibits multiple oncogenic pathways, resulting in reduced tumor growth, metastasis and angiogenesis in preclinical models [1] . In early clinical trials, ganetespib was well tolerated and demonstrated single-agent activity in patients with tumors harboring driver oncogenes such as mutated BRAF and KRAS, EML4-ALK translocations, and in tumors with HER2 overexpression [2] [3] [4] . The combination of ganetespib and taxanes is synergistic in preclinical studies [5, 6] , possibly due to downregulation of AKT signaling [7, 8] . It was of interest therefore to evaluate ganetespib in combination with docetaxel in patients with advanced NSCLC. A Phase 1 study [9] established the recommended schedule and doses as docetaxel at 75 mg/m 2 on Day 1 and ganetespib at 150 mg/m 2 on Days 1 and 15 of each 3-week cycle. The most common adverse events (AEs) associated with combination therapy were diarrhea, fatigue, neutropenia, and anemia. There was a strong scientific rationale for evaluating ganetespib in patients with baseline elevated LDH (eLDH) levels and those with mutated KRAS (mKRAS). eLDH is a prognostic factor in NSCLC [10, 11] . The LDH subunit A (LDH-A) expression is regulated by HIF1α [12] [13] [14] , a master transcription factor overexpressed in tumors with aggressive and treatment-resistant phenotypes [15, 16] . Therefore, eLDH might represent a surrogate biomarker for increased HIF1α tumor levels. Ganetespib decreased HIF1α expression in tumors both in preclinical models and in biopsies from ganetespib-treated rectal cancer patients [17] . 6 Several RAS effectors are Hsp90 clients including proteins in the MAPK pathway (ARAF, mutant BRAF, CRAF, p-ERK2, the MAPK agonist COT), and the PI3K/AKT signaling cascade (AKT, PDK1, p70S6K) [18, 19] . In a recent clinical study of ganetespib monotherapy in advanced NSCLC, 7/13 evaluable patients with mKRAS tumors had stable disease and transient tumor shrinkage [3] . Taken together, these considerations provide considerable support for evaluating ganetespib in patients with tumors harboring mutated KRAS.
GALAXY-1, a large, randomized Phase 2 study, was designed to determine whether ganetespib could enhance the efficacy of docetaxel in advanced NSCLC, and to identify patient subsets that would most benefit from this combination-therapy approach.
Patients and Methods
This global, multicenter, open-label, randomized Phase 2 study evaluated ganetespib in combination with docetaxel (combination arm) versus docetaxel alone (control arm) in patients with advanced NSCLC. An interim data review identified a safety signal of increased hemoptysis and lack of efficacy in non-adenocarcinoma patients, and therefore the eligibility criteria were amended to include only patients with adenocarcinoma histology. Key inclusion criteria were:
Stage IIIB or IV NSCLC (AJCC Cancer Staging Manual 7 th edition), ECOG performance status (PS) of 0 or 1, and disease progression following first-line therapy. Prior maintenance therapy was allowed. Patients with treated and stable brain metastases were eligible. Adequate hematology laboratory values and organ function were required for inclusion. Women of childbearing age were required to have a negative serum pregnancy test. Evaluation of EGFR mutational status and ALK translocation status was not required at study entry. Patients were excluded if they had serious cardiac illness, baseline QTc interval of >470 msec on electrocardiogram, uncontrolled high-risk arrhythmias, radiotherapy within 2 weeks before randomization, major surgery within 4 weeks before randomization, hemoptysis >grade 2 at randomization, or history of hypersensitivity to docetaxel. Patients with uncontrolled intercurrent illness and pregnant or lactating women were also excluded. The local institutional review board at each participating site approved the study protocol.
Study treatment
Patients were randomized (1:1) to therapy with ganetespib in combination with docetaxel 
Dose modifications
The most common AEs were managed with appropriate supportive care measures, treatment delays, and dose modification of study drugs. Treatment delays were allowed for a maximum of 14 days to allow for resolution of toxicity. At first instance of toxicity, study drugs were dose reduced to 80%. Further dose reductions required discussion with the medical monitor. In general, dose reductions were not performed for Grade 1 or 2 non-hematological toxicity. For Grade 3/4 toxicity, treatment was delayed until resolution to ≤Grade 1 and study drug was resumed with a dose reduction. If toxicity did not resolve despite a 2-week treatment delay, the patient was discontinued from study treatment. The dose of docetaxel was reduced for Grade 2 neuropathy, Grade 3/4 fatigue, Grade 3/4 neutropenia with fever, and elevation of ALT/AST to >3×ULN. Ganetespib dose was reduced for Grade 3/4 fatigue, Grade 3 QTc prolongation, or elevation of ALT/AST >3×ULN. The study required that medications associated with a high incidence of QTc prolongation be avoided or used with caution. Similarly, substrates of CYP3A4 and CYP2C19 were to be avoided.
Statistical design
The original study design had a primary endpoint of PFS in all enrolled advanced NSCLC patients. As interim data became available, an increased rate of hemoptysis was observed in patients with non-adenocarcinoma histology and the protocol population was changed to patients with lung adenocarcinoma histology. Two populations were identified as populations of interest: patients with eLDH and patients with mutated KRAS, based on biological rationale and preclinical and clinical data. The primary endpoints of the study were PFS in 2 subgroups of the adenocarcinoma population: patients with eLDH, and patients with mKRAS (a patient may belong to one or both groups). Key secondary endpoints were to compare the PFS and OS in all adenocarcinoma histology patients, as well as assessment of safety, and comparison of response rate. At the time of randomization, patients were stratified based on PS (ECOG 0 vs. 1), baseline total LDH (normal vs. elevated), smoking status (never-smoker, current, or former smoker), and interval since diagnosis of advanced NSCLC (<6 vs. >6 months). Time since diagnosis of advanced disease >6 months (determined by date of pathological reports) is indicative of sensitivity to prior chemotherapy and biological behavior of the disease, and this parameter was utilized to balance the treatment arms with respect to patients with more favorable prognosis.
For each of the primary endpoint subgroups, analyses were done at the 1-sided 0.05 level using Bonferroni adjustments for multiplicity (overall Type I Error was set at 0.10). If both analyses were significant, each of the key secondary analyses was to be tested at the 1-sided, 0.05 level. If only one of the primary analyses was significant, each of the two secondary analyses was to be performed at the 1-sided 0.025 level, and if no primary results were significant then secondary analyses would be performed as exploratory. For the eLDH and mKRAS subgroups with an estimated sample size of 120 and 80 patients each, respectively, the study had 90% power to detect a PFS HR of 0.5 favoring the combination arm, using a 1-sided stratified long rank test at the 5% significance level. For the overall adenocarcinoma group with a sample size of 240 patients, there was 88% power to detect PFS HR of 0.67 using a 1-sided stratified log rank test at the 5% significance level. The Cox proportional hazards (PH) model was used to estimate the unadjusted HR using only treatment in the model. To account for factors in the study in addition to treatment, the adjusted HRs were estimated using a stepwise Cox PH regression procedure, where treatment was included in all models. To enter the multivariate model, the prognostic factor had to be significant in a univariate model (P≤0.10), and to stay in the multivariate model the factor had to remain significant in the presence of all other factors (P<0.20). Potential prognostic factors included sex, age, total baseline target lesion size, geographic region, and stratification factors, including time since diagnosis of advanced NSCLC (≤6m, >6m). All analyses were conducted by the sponsor using SAS® version 9.3.
Results
Patient Baseline Characteristics
From July 2011 to May 2013, a total of 385 patients were enrolled and 381 received study treatment. Details regarding patient enrollment are provided in the CONSORT diagram ( Figure   1 ). In the adenocarcinoma population (N=253), baseline characteristics were balanced with the exception of a slightly higher representation of women and patients from the US and Western Europe in the combination arm (Table 1) . Never-smokers accounted for 25% (63/253) of the patients enrolled. Nearly 95% (241/253) of patients had received a prior platinum-based chemotherapy regimen and the use of prior pemetrexed in combination with platinum therapy was low at 23% (59/253). Seventy percent (177/253) of patients enrolled belonged to the >6 months from advanced NSCLC diagnosis group. Nine percent (11/125) and 14% (18/128) of the patients in the combination and control arms, respectively, had a history of brain metastasis. The median number of metastatic sites was comparable between the study arms (4 vs. 4). The number of patients with tumors harboring EGFR mutations was comparable between study arms (8 vs. 8) as was the number of wt EGFR patients (33/125 vs. 32/128). For the remainder of the patients there was insufficient tumor tissue to determine EGFR status.
Treatment delivery
Out of the 253 adenocarcinoma patients enrolled, 123 in the combination arm and 126 in the control arm received at least one dose of study treatment. Patients in the combination arm received more cycles of treatment (median of 6 cycles) than patients in the control arm (median of 4 cycles): ≥4 cycles (N=88, 72% vs. N=79, 63%), and ≥8 cycles of treatment (N=50, 41% vs. N=25, 20%). Forty patients (33%) received ganetespib as monotherapy after the combination regimen was completed.
Safety
The most common Grade ≥3 AEs for treated adenocarcinoma patients (N=249) were (combination vs. control): neutropenia 41% (50/123) vs. 42% (53/126), leukopenia 10% (12/123) vs. 6% (7/126), anemia 8% (10/123) vs. 2% (2/126) and neutropenia with fever 9% (11/123) vs. 5% (6/126) (see Table 2 for details). Diarrhea was more common with the use of ganetespib and the majority of episodes were Grade 1 or 2. Diarrhea occurred in the first 24-48 hours after the infusion of ganetespib and was managed with anti-motility agents. Dose reduction due to adverse events occurred in 23/123 (19%) and 13/126 (10%) patients in the combination and control arms, respectively. Discontinuation of study treatments due to serious adverse events (SAEs) was higher with combination therapy (N=11, 9% vs. N=6, 5%). Serious treatment-related AEs leading to hospitalization occurred in 20 (16%) and 7 (6%) of the patients in the combination and control groups, respectively. The difference in treatment-related SAEs leading to hospitalization is mainly attributed to increased rates of febrile neutropenia (combination vs. control; 10 vs 4 patients), diarrhea-related AEs (4 vs. 0), neutropenia (1 vs. 2), pneumonia (2 vs. 1) and hemoptysis (1 vs. 0). Deaths during study treatment, regardless of attribution, occurred in 21 13 (17%) and 16 (13%) patients, respectively, for the combination and control arms; such events were assessed as treatment related in 1 patient in the control group.
Efficacy
In the adenocarcinoma population 205 PFS events and 190 OS events had taken place at the time (Table 3) . Figure 3B ). This analysis did not include the 61 additional patients who were enrolled specifically for the co-primary endpoint analysis.
For the adenocarcinoma population Cox PH models for OS were fit for each of the prespecified stratification factors with only treatment, stratification factor, and the interaction between them in the model. Out of the four models fit, only the parameter estimate for the interaction term of treatment and time since diagnosis of advanced NSCLC was significant (P=0.0367) indicating that patients who were diagnosed with advanced NSCLC >6 months prior to study entry received a different benefit from the combination treatment than did those diagnosed ≤6m prior to study entry ( Table 3) Figure   4B ). Baseline characteristics of this subgroup were similar to those of the overall patient population. Conversely, adenocarcinoma patients who were diagnosed with advanced NSCLC ≤6-months prior to study entry (N=76) did not receive any treatment benefit from the 
Discussion
The goal of this large randomized Phase 2 study was to evaluate efficacy and safety of ganetespib in combination with docetaxel for second-line therapy of advanced NSCLC and to identify patient subgroups that could benefit from this combination therapy. The study did not meet its primary endpoints of improvement in PFS for eLDH or mKRAS patients, however, trends of improvements in ORR, PFS, and OS were observed in adenocarcinoma patients. The strongest signal of efficacy was seen in the exploratory analysis of the large subset of adenocarcinoma patients diagnosed with advanced NSCLC >6 months prior to study entry (~70% of the total adenocarcinoma population).
One possible explanation for the observed lack of efficacy in the mutant KRAS patient population was that the weekly dosing schedule for ganetespib might have been insufficient to durably suppress oncogenic KRAS signaling. To address this potential issue, future trials in this 16 patient subset should utilize alternate, more frequent ganetespib dosing schedules. In patients with elevated LDH levels, modest improvements in PFS were observed but failed to reach statistical significance. Interestingly, overall survival in these patients was improved following combination therapy and therefore in the ongoing Phase 3 study (GALAXY-2) OS in eLDH patients has been included as a secondary endpoint. Randomized studies conducted in the salvage-treatment setting of advanced NSCLC have utilized different prognostic criteria to stratify patients, such as best response to prior therapy, time since diagnosis of advanced disease, and time since last chemotherapy. The use of >6 months since diagnosis of advanced disease as a stratification factor was pre-specified and allowed differential evaluation of efficacy in patients with better (>6 months) and worse (<6 months) prognosis. Unlike the treatment effect observed in the >6 month population, no efficacy signal was observed in the group diagnosed <6 months prior to study entry. This finding suggests that mechanisms of resistance to chemotherapy, or underlying aggressive disease, might not be sensitive to mitigation by ganetespib. Indeed, preclinical studies show that the functional mitochondrial caspase pathway is critical to ganetespib's anti-cancer effects (D. Fennell, unpublished observations). Archived tumor tissue was collected in nearly all patients enrolled for the purpose of KRAS mutation testing. The next priority was accorded to EGFR mutation testing, which was only possible in a subset of patients (approximately 30%) due to limited tissue availability. Equal numbers of patients were found to have EGFR mutations in each treatment arm; from the available data, EGFR mutation status was not a determinant of sensitivity to ganetespib. We were unable to test for anaplastic lymphoma kinase (ALK) gene rearrangement due to insufficient tissue. Though ALK is a sensitive client protein for Hsp90, given the low prevalence of this gene rearrangement in NSCLC, it is highly 17 unlikely that activity in ALK-positive patients alone is adequate to drive the overall efficacy of the study.
Given the broad set of putative targets for Hsp90 inhibition, collection of adequate tumor tissue is critical for future studies. A correlation analysis of clinical outcomes in GALAXY-1 with results from tumor tissue profiling using the Oncoscan assay is underway and will be published separately. The findings from the current study prompted the ongoing confirmatory GALAXY-2 Phase 3 trial, with a sample size of 850, in patients with NSCLC of adenocarcinoma histology, diagnosed with advanced disease >6 months prior to study entry. 
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